Cue Biopharma Stock Performance
| CUE Stock | USD 1.03 0.11 9.65% |
Cue Biopharma holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cue Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cue Biopharma is expected to be smaller as well. Use Cue Biopharma potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to analyze future returns on Cue Biopharma.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | 09/26/2024 |
2 | Cue BiopharmaAnnounces Pricing of 12.0 Million Public Offering | 09/27/2024 |
3 | Cue BiopharmaAnnounces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers th Annual Meeting | 10/04/2024 |
4 | Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule 16b-3 | 10/09/2024 |
5 | Alnylam Pharmaceuticals Reports Q3 Loss, Lags Revenue Estimates | 10/31/2024 |
6 | Axsome Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/12/2024 |
7 | Cue Biopharma Inc Q3 2024 Earnings EPS of 0.17 Beats Estimate, Revenue Surges to 3. ... | 11/14/2024 |
8 | Jefferies cuts Cue Biopharma shares target, retains buy rating on potential | 11/15/2024 |
9 | Cue Biopharmato Participate in Fireside Discussion at the Piper | 11/25/2024 |
10 | Acquisition by Driscoll Frederick W of 10000 shares of Cue Biopharma at 12.28 subject to Rule 16b-3 | 11/26/2024 |
11 | KOJO and CUE Join Forces to Bring Cutting-Edge Fan Engagement Technology to Australia and New Zealand | 11/29/2024 |
| Begin Period Cash Flow | 51.8 M |
Cue |
Cue Biopharma Relative Risk vs. Return Landscape
If you would invest 59.00 in Cue Biopharma on September 6, 2024 and sell it today you would earn a total of 44.00 from holding Cue Biopharma or generate 74.58% return on investment over 90 days. Cue Biopharma is generating 1.4809% of daily returns assuming volatility of 11.9795% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than Cue, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Cue Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cue Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cue Biopharma, and traders can use it to determine the average amount a Cue Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1236
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CUE | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.98 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.48 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Cue Biopharma is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cue Biopharma by adding it to a well-diversified portfolio.
Cue Biopharma Fundamentals Growth
Cue Stock prices reflect investors' perceptions of the future prospects and financial health of Cue Biopharma, and Cue Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cue Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.91) % | ||||
| Current Valuation | 49.31 M | ||||
| Shares Outstanding | 63.35 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.85 X | ||||
| Price To Sales | 7.87 X | ||||
| Revenue | 5.49 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (50.73 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 14.7 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (39.96 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Market Capitalization | 65.25 M | ||||
| Total Asset | 61.53 M | ||||
| Retained Earnings | (301.19 M) | ||||
| Working Capital | 34.37 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
About Cue Biopharma Performance
By analyzing Cue Biopharma's fundamental ratios, stakeholders can gain valuable insights into Cue Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cue Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cue Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.87) | |
| Return On Capital Employed | (1.17) | (1.23) | |
| Return On Assets | (0.82) | (0.87) | |
| Return On Equity | (1.37) | (1.44) |
Things to note about Cue Biopharma performance evaluation
Checking the ongoing alerts about Cue Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cue Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cue Biopharma is way too risky over 90 days horizon | |
| Cue Biopharma has some characteristics of a very speculative penny stock | |
| Cue Biopharma appears to be risky and price may revert if volatility continues | |
| Cue Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M. | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cue Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: KOJO and CUE Join Forces to Bring Cutting-Edge Fan Engagement Technology to Australia and New Zealand |
- Analyzing Cue Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cue Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Cue Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cue Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cue Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cue Biopharma's stock. These opinions can provide insight into Cue Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |